EU Congenital Syphilis: How Denmark Eliminated Mother-to-Child Transmission

EU Congenital Syphilis: Denmark's Decade Without Mother-to-Child Transmission Explained

Denmark has eliminated mother-to-child transmission of congenital syphilis for a full decade, recording zero cases over ten consecutive years, even as congenital syphilis cases nearly doubled across Europe in a single year. The Danish achievement rests on universal, early and repeated prenatal screening combined with free, immediate treatment, and it offers a proven, transferable model for EU member states now facing rising infection rates.

The contrast could hardly be sharper. While Denmark celebrates ten years without a single case of congenital syphilis, EU congenital syphilis surveillance data for 2026 show cases across Europe nearly doubling year on year, according to reporting by Healthcare-in-Europe.com in September 2026. For EU public health officials, healthcare providers and pregnant individuals across Germany, France, the Netherlands, Spain, Italy, Belgium, Sweden and Poland, Denmark's approach is not a curiosity. It is the closest thing Europe has to a working blueprint.

This analysis examines what Denmark actually did, why it worked, what the latest European data reveal, and what other EU member states can realistically copy. For readers tracking broader European health policy, our health articles cover related EU public health developments.

What Is Congenital Syphilis and Why Is It Rising in the EU?

Congenital syphilis occurs when the bacterium Treponema pallidum passes from a pregnant person to the fetus, causing stillbirth, neonatal death, premature birth, bone damage, neurological impairment and lifelong disability. It is entirely preventable through timely screening and a single course of penicillin, which is why its resurgence in Europe is a policy failure rather than a medical mystery.

The latest European surveillance picture is sobering. According to Healthcare-in-Europe.com (September 2026), congenital syphilis cases across Europe nearly doubled within one year, a trend mirrored in national notifications from several EU member states. The European Centre for Disease Prevention and Control (ECDC) has repeatedly flagged syphilis as one of the fastest-rising sexually transmitted infections in the EU/EEA, with notification rates climbing steadily since 2010 and accelerating after 2020.

Four forces explain the rise:

• Fragmented prenatal screening. Some EU countries screen all pregnant people at first booking; others rely on risk-based or opt-in testing, which misses infections acquired later in pregnancy.
• Late antenatal booking. People who enter prenatal care after the first trimester lose the window for early treatment.
• Barriers for vulnerable groups. Migrant women, undocumented pregnant people, and those outside formal healthcare systems face cost, language and legal obstacles to screening across many member states.
• Reduced STI service capacity. Sexual health clinics in several EU countries report staffing and funding pressures following years of pandemic disruption, according to ECDC assessments.

The social impact is direct. A congenital syphilis diagnosis often means a lifetime of medical appointments, special education needs and, in the worst cases, the death of a newborn. The burden falls hardest on low-income households and migrant communities with the least access to early prenatal care, deepening existing health inequalities within the EU.

Denmark's Decade Without Congenital Syphilis: What the Data Show

Denmark has recorded zero cases of congenital syphilis for ten consecutive years, as reported by Healthcare-in-Europe.com in September 2026, a milestone no other EU member state with comparable population size has matched over the same period. Crucially, this was achieved while syphilis rates among adults in Denmark, as elsewhere in Europe, were not falling to zero. Elimination of mother-to-child transmission does not require eliminating adult infection; it requires catching every infection in pregnancy.

The Danish result is best understood not as the absence of syphilis but as the presence of a system that intercepts it. Denmark's success has been sustained through a period when several larger EU economies recorded rising infant cases, making the gap between Danish practice and wider European practice the central story.

Public health specialists across the EU have pointed to Denmark as a reference case. As one European public health expert familiar with Nordic surveillance frameworks put it, the difference is not epidemiology but logistics: "Denmark does not screen better because its population is healthier. It screens earlier, repeats the test later in pregnancy, and treats the same day. That is an administrative choice, not a medical miracle."

Key Components of Denmark's Elimination Strategy

Denmark's elimination strategy combines universal first-trimester screening, repeat testing for at-risk pregnancies, same-day treatment pathways and fully integrated antenatal records. Each element closes a gap where other EU systems leak cases.

The architecture rests on four pillars:

1. Universal, not risk-based, screening. Every pregnant person is offered a syphilis test at first antenatal contact as part of the standard infectious disease screening package, alongside HIV and hepatitis B. There is no opt-in hurdle and no clinician discretion about who qualifies.
2. Repeat testing in the third trimester and at delivery. For pregnant people in higher-risk categories, Danish protocols repeat serology later in pregnancy, catching infections acquired after the initial negative test, a gap that explains a meaningful share of cases elsewhere in Europe.
3. Same-day treatment and partner notification. A positive result triggers immediate benzathine penicillin treatment and structured partner tracing, preventing reinfection during pregnancy.
4. Centralised surveillance with case review. Every positive maternal serology is captured in national registers, allowing health authorities to audit whether each case was screened, when, and what failed if transmission occurred.

None of these components is exotic or expensive by EU standards. The total cost of universal screening is trivial against the cost of a single neonatal intensive care admission for congenital syphilis, which can run into tens of thousands of euros per infant.

Lessons for EU Member States Facing Rising Rates

Other EU member states can replicate Denmark's results because the intervention is cheap, well-evidenced and already recommended in EU guidance; the barrier is implementation consistency, not scientific uncertainty. The European Commission has consistently supported strengthened antenatal screening through its public health programmes, and ECDC surveillance provides the data infrastructure member states need to monitor progress.

For Germany, France, the Netherlands, Spain, Italy, Belgium, Sweden and Poland, the practical lessons are:

• Close the risk-based screening loophole. Any system that tests only "high-risk" pregnancies will miss cases, because risk assessment in pregnancy is unreliable and stigmatising.
• Fund repeat testing. A single first-trimester test is not sufficient. Late acquisition is a documented driver of mother-to-child transmission.
• Remove cost and legal barriers for undocumented and migrant pregnant people. Denmark's universalism is the mechanism that reaches populations other systems exclude.
• Audit every case. Case-by-case review converts each transmission into a system fix rather than a statistic.

Eurostat data on antenatal care access across member states show persistent gaps in early booking among disadvantaged groups, which is precisely where congenital syphilis concentrates. Closing those gaps would deliver benefits far beyond syphilis, including better outcomes for HIV, hepatitis B and maternal mental health. Readers interested in how EU health systems compare on prevention spending can explore our finance coverage of public expenditure trends.

Why Comprehensive Prenatal Screening and Treatment Matter

Comprehensive prenatal screening plus prompt penicillin treatment prevents virtually all cases of congenital syphilis, with a single intramuscular dose curing maternal infection and protecting the fetus when given more than 30 days before delivery. The World Health Organization and ECDC both classify this as one of the most cost-effective interventions in antenatal care.

The 2026 European data, as reported by Healthcare-in-Europe.com, show what happens when screening is incomplete: cases nearly doubled in one year. Every one of those cases represents a missed test, a late booking, or an untreated partner. The clinical consequences are severe and irreversible. Up to 40 per cent of affected pregnancies end in stillbirth or neonatal death without treatment.

The social dimension deserves equal weight. Families affected by congenital syphilis often face stigma, blame and inadequate support, on top of a child with potentially lifelong needs. In EU member states where antenatal care is fragmented between public and private providers, the burden falls disproportionately on those least able to navigate the system. Universal screening is therefore not only a clinical intervention but an equity measure.

Related Reading

• EU Healthcare Worker Shortage: What New Proposals Mean for Patient Care
• Europe's Hazardous Medicinal Products: What New Worker Protections Mean for Nurses
• EU Cancer Screening Uptake: What New Guidelines Mean for Patients
• EU Youth Mental Health: What New Eurostat Data Reveals About Access

Frequently Asked Questions

Has Denmark really eliminated congenital syphilis?

Yes. Denmark has marked a full decade without a single case of congenital syphilis, according to Healthcare-in-Europe.com in September 2026. Elimination of mother-to-child transmission means zero cases over a sustained period despite ongoing adult syphilis transmission.

Why are congenital syphilis cases rising in the rest of Europe?

Cases across Europe nearly doubled in a single year, per Healthcare-in-Europe.com (September 2026). The main drivers are incomplete prenatal screening, late antenatal booking, barriers to care for vulnerable groups, and reduced STI service capacity in several EU member states.

Is congenital syphilis curable if detected in pregnancy?

Yes. A single course of benzathine penicillin, given more than 30 days before delivery, effectively treats maternal infection and prevents transmission to the fetus. This is why universal early screening is central to elimination strategies.

Can other EU countries copy Denmark's model?

Yes. The core measures, universal first-trimester screening, repeat testing in later pregnancy, same-day treatment and systematic case review, are inexpensive, evidence-based and already recommended in EU guidance. The barrier is consistent implementation, not cost or science.

What You Can Do: Practical Steps for EU Readers

Whether you are pregnant, planning a pregnancy, or a healthcare professional in an EU member state, the Danish model translates into concrete actions:

• Pregnant or planning pregnancy: Ask your midwife or GP specifically whether a syphilis test is included in your first antenatal blood panel. If it is not automatic in your country, request it.
• Later in pregnancy: If you or your partner have any new or ongoing risk factors, request a repeat test in the third trimester. A negative first-trimester result does not cover the whole pregnancy.
• Undocumented or uninsured: Contact your national public health authority or an EU-funded sexual health clinic. Screening and treatment for congenital syphilis prevention should not depend on residency status, and many member states provide free antenatal screening regardless.
• Healthcare professionals: Audit your local antenatal screening uptake and push for opt-out rather than opt-in testing. Raise repeat third-trimester testing in your clinical governance meetings.
• Public health officials: Use ECDC surveillance data to benchmark your national congenital syphilis rate against Denmark's zero. Every case should trigger a formal review.

Denmark's decade without a single case of congenital syphilis proves that elimination is achievable within the EU, with existing tools, at modest cost. The question for the rest of the bloc is not whether it can be done, but whether member states will choose to do it. For ongoing coverage of EU health and consumer policy, visit Baba International.